Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
07 nov. 2018 16h00 HE
|
Immunomedics
Phase 2 Platform Study to Evaluate the Combination of Imfinzi® (Durvalumab) and Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer Who Progressed on or after Immune Checkpoint Inhibitor...
Immunomedics to Report First Quarter Fiscal 2019 Results and Host Conference Call and Webcast on November 7, 2018
31 oct. 2018 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership
12 sept. 2018 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J. and INCHEON, South Korea, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) and Samsung BioLogics Co., Ltd. today announced the companies have entered into a...
Immunomedics Announces Participation in Upcoming Healthcare Conferences
28 août 2018 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
23 août 2018 16h00 HE
|
Immunomedics
Biologics License Application (BLA) Accepted for Filing and Granted Priority Review by the U.S. Food and Drug Administration (FDA) U.S. Commercial Launch Preparations on Track Lifecycle Management...
Immunomedics to Report Fourth Quarter and Fiscal Year 2018 Results and Host Conference Call and Webcast on August 23, 2018
16 août 2018 16h35 HE
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions
30 juil. 2018 08h00 HE
|
Immunomedics
Clinical Collaboration with Yale University to Evaluate Sacituzumab Govitecan in Two Phase 2 Studies in Endometrial and Cervical Cancers Research Collaborations with Yale University, Memorial Sloan...
Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers
23 juil. 2018 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., July 23, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
18 juil. 2018 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Closing of Public Offering of Common Stock
15 juin 2018 11h39 HE
|
Immunomedics
MORRIS PLAINS, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...